Board of Directors

COMMITTED TO CHANGING THE FACE OF CANCER TREATMENT

The BioCanRx Board of Directors is responsible for ensuring financial accountability, scientific excellence, knowledge exchange and operational efficiency. The board approves policies and procedures consistent with the goals and mission of the network. It also determines the mandate, membership, authority and makeup of committees.

The Board provides leadership and direction to BioCanRx so that it remains on target with respect to its strategic plan and commitment to the NCE mandate.

MEMBERS OF THE BOARD:


Ken Newport Chair, Board of Directors	Dr. John Bell Scientific Director, BioCanRx Senior Scientist, The Ottawa Hospital Professor, uOttawa	Ela Borenstein Vice President, Venture Capital Incentivized Program Business Development Bank of Canada (BDC)	Dr. Josée Brisebois Head of Medical, Incyte Canada / Medical Affairs with oversight of Clinical & Regulatory Affairs

Craig Earle Vice-President, Cancer Control at the Canadian Partnership Against Cancer	Karimah Es Sabar Chief Executive Officer & Partner, Quark Venture LP	Doreen Hume Partner, Audit & Assurance, Deloitte Canada	Debra Lynkowski Chief Operating Officer The Ottawa Hospital Research Institute

Antonia Palmer Co-Founder at Ac2orn: Advocacy for Canadian Childhood Oncology Research Network	Dr. David Poon Vice President Business Development and Alliance Management, Zymeworks Inc.	Dr. John Stagg Associate Professor, Faculty of Pharmacy at the University of Montreal Lab Head at the CHUM Hospital Research Centre	Dr. Christine Williams Deputy Director, Ontario Institute for Cancer Research (OICR)

Russell Williams Senior Vice President, Mission, Diabetes Canada